pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
the cabinet
Drugs
6,918
products tracked ·
6,918
matching
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
view
list
cards
Preclinical
MIRA-55
Anxiety Disorders
$MIRA
MIRA PHARMACEUTICALS, INC.
0
catalysts
Phase 2
MIT-001
Oral Mucositis
MitoImmune Therapeutics Inc
0
catalysts
MITOXANTRONE
MITOXANTRONE (MITOXANTRONE)
HOSPIRA
0
catalysts
Phase 2
MIV-711
Osteoarthritis
Medivir AB
catalysts
← prev
page 108 of 231
next →
131
Pain
89
Neurology
1
0
MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT
MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE)
SpecGx LLC
0
catalysts
Phase 3
MK-1406
Pandemic Influenza
$MRK
Merck & Co., Inc.
0
catalysts
Phase 2
MK-2214
Alzheimer's Disease
$MRK
Merck & Co., Inc.
0
catalysts
Phase 2
MK-3795
Von Hippel-Lindau Syndrome
$MRK
Merck & Co., Inc.
0
catalysts
Phase 2
MK-6194
Ulcerative Colitis
$MRK
Merck & Co., Inc.
0
catalysts
Marketed
ML-061
Docivyx (docetaxel)
Adenocarcinoma Of The Gastroesophageal Junction
Meridian Laboratories Inc
0
catalysts
Preclinical
MLN-33
Melanoma
$CNBX
CNBX Pharmaceuticals Inc.
0
catalysts
Phase 2
MNV-101
Pearson Syndrome
Minovia Therapeutics Ltd
0
catalysts
Phase 2
MNV-201
Pearson Syndrome
Minovia Therapeutics Ltd
0
catalysts
Phase 1
MO-03
Metastatic Renal Cell Carcinoma
Osel Inc
0
catalysts
Phase 1
MOMA-313
Metastatic Breast Cancer
Moma Therapeutics Inc
0
catalysts
Preclinical
MOMA-989
Unspecified Cancer
Moma Therapeutics Inc
0
catalysts
MOMETASONE FUROATE MONOHYDRATE
MOMETASONE FUROATE MONOHYDRATE (MOMETASONE FUROATE MONOHYDRATE)
AUROBINDO PHARMA
0
catalysts
MONTELUKAST
MONTELUKAST (MONTELUKAST)
MACLEODS PHARMS LTD
0
catalysts
Phase 2
MORF-057
Crohn's Disease (Regional Enteritis)
Eli Lilly and Co
0
catalysts
MOXIFLOXACIN OPHTHALMIC SOLUTION
MOXIFLOXACIN OPHTHALMIC SOLUTION (MOXIFLOXACIN OPHTHALMIC SOLUTION)
ALEMBIC
0
catalysts
Preclinical
MP-004
Retinitis Pigmentosa (Retinitis)
MIRAMOON Pharma SL
0
catalysts
Phase 2
MP-0712
Neuroendocrine Tumors
$MOLN
MOLECULAR PARTNERS AG
0
catalysts
Phase 2
MP-101
dimiracetam [INN]
Amyotrophic Lateral Sclerosis
Mitochon Pharmaceuticals Inc
0
catalysts
Phase 2
MP-1032
Coronavirus Disease 2019 (COVID-19)
MetrioPharm AG
0
catalysts
Phase 2
MPB-1734
Solid Tumor
MegaPro Biomedical Co Ltd
0
catalysts
Preclinical
MPB-2354
Rheumatoid Arthritis
MegaPro Biomedical Co Ltd
0
catalysts
Phase 2
MRG-002
Gastric Cancer
Shanghai Miracogen Inc
0
catalysts
Phase 2
MRG-004A
Solid Tumor
Shanghai Miracogen Inc
0
catalysts
Phase 2
MRM-3379
Fragile X Syndrome
$MIRM
Mirum Pharmaceuticals, Inc.
0
catalysts
Phase 2
MRT-2359
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
$GLUE
Monte Rosa Therapeutics, Inc.
0
catalysts
